All Solid Tumors

Cancer Type

Tumor Tissue (FFPE)

Specimen Requirements

8 Working Days

Turnaround Time ¹

ACTDrug®+ is an NGS-based test, which sequences 40 druggable genes, 13 fusion genes, and more than 350 fusion transcripts simultaneously from cancer specimens.

Targeted Cancer Genomic Profiling Service

40

Cancer Genes

13

Fusion Genes

350

Fusion Transcripts

Hallmarks

Drug-Target-Based Panel

Sequences 40 actionable genes,13 fusion genes and more than 350 fusion transcripts with genetic alterations.

Short Turnaround Time

Provides professional solutions within 8 working days (starting from the date of receipt of approved samples at our CAP-accredited laboratory).

High Sensitivity

Uses the NGS platform for microscale specimens.

Tailored Drug Options

Analyzes single nucleotide variation (SNV), small insertion/deletion (InDel), copy number variation (CNV)and fusion gene to provide tailored drug options.

Pioneering Bioinformatics

Integrates cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science and pharmaceutical biology to provide insightful interpretation of the data analyses.

Summary

Select Drugs for Your Cancer Patient

Provides tailored drug options through precise genomic profiling for important actionable genes.

A Precise Choice for Cancer Genomic Profiling

ACTDrug®+ is a next-generation sequencing (NGS)-based assay, which sequences 40 actionable genes, 13 fusion genes and more than 350 fusion transcripts simultaneously from cancer specimens in our CAP-accredited laboratory. This assay is specially designed for patients with breast, lung, colorectal or gastric cancers, providing tailored genomic profiling and recommendations of targeted drugs approved by the US FDA.

Explore Various Genetic Alterations for More Precise Therapeutic Implication

ACTDrug®+ performs various genetic variation analyses. In addition to single nucleotide variation (SNV) and small insertion/ deletion (InDel), it provides copy number variation (CNV) analysis for 22 genes and fusion gene detection for more precise determination of potential implications.

For All Solid Tumors

Selects the most suitable treatment for newly diagnosed patients based on actionable genetic mutations.

Precise Reporting

Considers targeted therapies and hormonal therapies approved by US FDA or in clinical trials.

Technical Specifications

Next Generation Sequencing (NGS)

40 actionable genes

Specimen Requirements2

Tumor tissue (FFPE)

Sequencing Mean Depth

≥ 800 x

Hotspots

>3800

ACTFusion™

Comprehensive testing of 13 fusion genes and more than 350 fusion transcripts

Documentation

Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download

Disclaimers / Footnotes

  1. Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
  2. Please refer to our specimen instructions.

Book a Test

Explore the immense possibilities and promising future of precision medicine. Together, let us unlock the power of genomic testing and personalize cancer care for the most effective treatment.

Get Started